Picture Kentro Design Corporate and Web Design Berlin 600x60px
Collaboration › Details

JnJ–Protectimmun: asthma drug, 201509 collab research JnJ Innovation funding preclinical study at Imperial College Protectimmune lead candidate


Period Period 2015-09-28
Organisations Partner, 1st Johnson & Johnson Innovation – JJDC, Inc.
  Group Johnson & Johnson (JnJ) (Group)
  Partner, 2nd Protectimmun GmbH
Products Product asthma drugs
  Product 2 preclinical research

Protectimmun GmbH. (9/28/15). "Press Release: Protectimmun Teams Up With Johnson & Johnson Innovation and Imperial College under a Research Funding Agreement". Gelsenkirchen.

Protectimmun GmbH, a biopharmaceutical R&D company, announced today that it has entered into a research funding agreement with Janssen Biotech, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, and Imperial College, London. The research agreement, facilitated by Johnson & Johnson Innovation, will fund preclinical research conducted at Imperial College by Prof Clare Lloyd with one of Protectimmun’s lead candidates in a proof-of-concept disease model of allergic asthma developed by Prof Lloyd.

“We are very pleased about the opportunity to strengthen and expand our preclinical data package for this program through this collaboration”, said Marion Kauth, Ph.D., co-founder and Chief Executive Officer of Protectimmun. “This agreement strongly supports our ambition to pave the way for a disruptive first-in-class approach to combat allergic asthma and hay fever.”

Protectimmun focusses on new approaches in the prevention and therapy of allergic and chronic inflammatory diseases. Its innovative concept for product development is based on the identification of natural substances and bacteria with immunomodulatory properties from particular farm environments which are selectively transferred into pharmaceutical applications. Promising candidates that were successfully tested in proof-of-concept animal models of asthma are currently in mid- to late-stage preclinical development.

”It is impressive to see Johnson & Johnson Innovation’s strong commitment to creating new types of early-stage R&D collaborations to foster innovative healthcare solutions”, added Marcus Peters, PhD, board member of Protectimmun.


Protectimmun GmbH
Marion Kauth, PhD, CEO
+49 209 389 66 556

Record changed: 2017-04-02


Picture Fairtec GmbH We Optimise the ROI of Your Event 600x60px

More documents for Johnson & Johnson (JnJ) (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at (European life sciences) and (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture [LSUS] – The Business Web Portal 600x60px

» top